scholarly journals Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema

2013 ◽  
pp. 1423 ◽  
Author(s):  
Elena Pacella ◽  
Annarita Vestri ◽  
Paolo Turchetti ◽  
Roberto Muscella ◽  
Mary Carbotti ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Preliminary Results ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone ◽  
Persistent Diabetic Macular Edema

Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema

2012 ◽  
Vol 228 (2) ◽  
pp. 117-122 ◽  
Author(s):  
Ilaria Zucchiatti ◽  
Rosangela Lattanzio ◽  
Giuseppe Querques ◽  
Lea Querques ◽  
Claudia Del Turco ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone ◽  
Persistent Diabetic Macular Edema

scholarly journals Intravitreal Injection of Ozurdex® Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up

2016 ◽  
Vol 8 ◽  
pp. OED.S38028 ◽  
Author(s):  
Fernanda Pacella ◽  
Adriana Francesca Ferraresi ◽  
Paolo Turchetti ◽  
Tommaso Lenzi ◽  
Rosalia Giustolisi ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Slow Release ◽  
Post Injection ◽  
Dexamethasone Implant ◽  
Corrected Visual Acuity ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone ◽  
Persistent Diabetic Macular Edema

Aim To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). Methods A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (TO) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection. Results Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up. Conclusion Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.

Sign in / Sign up

Export Citation Format

Share Document